Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2022-02-28 Audit Report / Informat…
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
Audit Report / Information 2021
Audit Report / Information Classification · 99% confidence The document is explicitly titled "Auditor's Report on Grifols, S.A. and Subsidiaries" and contains the section "Independent Auditor's Report on the Consolidated Annual Accounts" with an "Opinion" section detailing the audit findings for the year ended 31.12.2021. This content is characteristic of a formal audit report, which aligns with the definition for 'Audit Report / Information' (AR). Although it references the annual accounts, the primary document presented here is the auditor's opinion and report on those accounts, not the full Annual Report (10-K) itself, nor is it a mere announcement of a report (RPA/RNS). FY 2021
2022-02-28 English
Annual Report 2021
Annual Report Classification · 100% confidence The document contains a detailed consolidated annual financial report for Grifols, S.A. for the fiscal year ended December 31, 2021. It includes a declaration of responsibility by the board members, consolidated financial statements such as balance sheets, income statements, cash flow statements, and notes on accounting principles and risk management. The presence of comprehensive financial data, notes, and management analysis indicates this is the full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-02-28 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 99% confidence The document is titled 'MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS' (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) made by a director (TOMÁS DAGÁ GELABERT) of the issuer (GRIFOLS, S.A.). This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors).
2021-12-13 Spanish
FORM 6-K
Regulatory Filings
2021-11-17 English
FORM 6-K
Regulatory Filings
2021-10-26 English
Continuación de la Información Privilegiada presentada el 17 de septiembre de 2021.
M&A Activity Classification · 99% confidence The document is a formal communication from Grifols, S.A., explicitly labeled as "INFORMACIÓN PRIVILEGIADA" (Inside Information) and referencing compliance with Article 226 of the Spanish Securities Market Law. The core content discusses the approval by the German financial supervisory authority (BaFin) of the offer document for a voluntary public takeover bid (tender offer) for Biotest AG shares. This clearly relates to a corporate action involving the acquisition or takeover of another company. Based on the provided definitions, the most appropriate category is 'M&A Activity' (Code: TAR), which covers merger proposals or takeover bids.
2021-10-26 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.